Covid-19 coronavirus: key regulatory and enforcement risks
22 April 2020
The Covid-19 coronavirus pandemic has brought unprecedented global challenges across all industries. Each day brings new medical information, a new projection on the economic impact, and seemingly never-ending uncertainty about the future.
As companies grapple with this new reality and position themselves to survive the crisis, and then thrive once the crisis ends, Allen & Overy has been actively monitoring the risks companies face from a regulatory and enforcement perspective. While companies must rightly focus on their pressing short-term needs and commercial issues, a key lesson from the 2008 financial crisis should not be forgotten: the economic turmoil sparked a years-long wave of regulatory and enforcement action targeting crisis-era conduct.
With that lesson in mind, this note contains guidance across a range of regulatory and enforcement risks that companies across different industries are grappling with during the Covid-19 crisis, including securities, commodities and related derivatives, antitrust, anti-corruption, anti-money laundering, sanctions, foreign investment, and political law.
We identify key risks and suggest mitigation strategies. More in-depth analyses on specific issues and industries can be found below, and will be updated.
- Covid-19: Global Merger Review Update
- Covid-19: Global Application of Antitrust Rules
- Covid-19 and the EU State aid response